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ADFnucleotidase (cN-II) is an ubiquitous nucleotide hydrolysing enzyme. The enzyme
is widely distributed and its amino acid sequence is highly conserved among vertebrates. Fluctuations of cN-
II activity have been associated with the pathogenesis of neurological disorders. The enzyme appears to be
involved in the regulation of the intracellular availability of the purine precursor IMP and also of GMP and
AMP, but the contribution of this activity and of its regulation to cell metabolism and to CNS cell functions
remains uncertain. To address this issue, we used a vector based short hairpin RNA (shRNA) strategy to
knockdown cN-II activity in human astrocytoma cells. Our results demonstrated that 53 h after transduction,
cN-II mRNA was reduced to 17.9±0.03% of control cells. 19 h later enzyme activity was decreased from 0.7±
0.026 mU/mg in control ADF cells to 0.45±0.046 mU/mg, while cell viability (evaluated by the MTT reduction
assay) decreased up to 0.59±0.01 (fold vs control) and caspase 3 activity increased from 136±5.8 pmol min−1
mg−1 in control cells to 639±37.5 pmol min−1 mg−1 in silenced cells, thus demonstrating that cN-II is
essential for cell survival. The decrease of enzyme activity causes apoptosis of the cultured cells without
altering intracellular nucleotide and nucleoside concentration or energy charge. Since cN-II is highly
expressed in tumour cells, our ﬁnding offers a new possible therapeutical approach especially against
primary brain tumours such as glioblastoma, and to ameliorate chemotherapy against leukemia.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
cN-II is an enzyme belonging to the 5′-nucleotidase family (5′-NT,
EC 3.1.3.5) recently included into the Haloacid dehalogenase (HAD)
superfamily [1]. 5′-NT comprises a large and complex group of
enzymes differing in subcellular location, substrate speciﬁcity and
showing a peculiarly low sequence homology. Nevertheless, they
presumably share the same reaction mechanism [1]. The family of
mammalian 5′-NTs to date includes seven forms: one ectosolic,
bound to the plasma membrane by a glycosyl phosphatidylinositol
anchor, onemitochondrial (mdN) and ﬁve cytosolic (cN-I a and b, cN-
II, cN-III, cdN) [2,3]. They are involved in the nucleotide metabolism
catalysing the hydrolysis of the 5′-phosphates of either ribonucleo-39 050 2211460.
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l rights reserved.tides or deoxyribonucleotides, although some enzymes are able to
hydrolyse also the phosphates esteriﬁed in 2′ and 3′ position of
nucleotides. Hence the physiological role of 5′-NT should be the
regulation of ribo- and deoxyribonucleotide pools, playing a pivotal
role in the cellular energetic balance, metabolic regulation and cell
replication. Furthermore, according to their different substrate
speciﬁcity, cellular location and tissutal distribution, each protein
plays a speciﬁc role within the cell in order to suit the metabolic
needs of a particular tissue or cell type. Among 5′-NTs, the cytosolic
5′-nucleotidase II (cN-II) is awidespread enzymewhose presence has
been detected in mammals (human, rat, pig and calf), birds (chicken
and goose), a frog (Rana catesbeiana), ﬁshes (teleosts and an ela-
smobranch), reptiles (a turtle, a tortoise, snakes) and in the in-
vertebrate Artemia [4]. Human cN-II gene is located in chromosome
10q24.32, and the enzyme protein in its active form is a homo-
tetramer in which each subunit has a molecular mass of 60–70 kDa.
cN-II shows a marked afﬁnity for all 6-hydroxypurine nucleotides
hence it is also called IMP/GMP 5′-nucleotidase [5–7]. The enzyme
possesses both phosphatase and phosphotransferase activities. The ca-
talysis proceeds through the formation of an enzyme-phosphate co-
valent intermediate and we previously demonstrated that this
phosphorylation occurs at Aspartate 52 included into a DXDXT
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superfamily [8].
cN-II is a Mg2+ dependent allosteric enzyme activated by ADP, ATP,
2,3-bisphosphoglycerate (BPG), decavanadate [9,10], diadenosine
polyphosphates, mainly Ap4A [11] and inhibited by inorganic
phosphate. Higher cN-II activity has been detected in tissues with a
high turnover of nucleic acids and their precursors, such as spleen,
testis, ﬁbroblasts and endothelial cells, while low activity is present in
brain, heart, skeletal muscle and erythrocytes [12]. On the bases of our
knowledge on cN-II properties we may speculate that the role of this
enzyme is to hydrolyse the excess of IMP deriving from de novo
synthesis or from salvage pathway, when the cell energy charge is
high; on the other hand, in ischemic conditions, with ATP depletion,
cN-II activity lessens remarkably, leading to accumulation of IMP
deriving from ATP hydrolysis, thus preventing the loss of purine
compounds [1,5,9,10,13,14]. It seems also that cN-II participates in the
excretion of proteic ammonium as uric acid not only in birds, but also
in mammals through the dephosphorylation of the excess of IMP
deriving from de novo synthesis in response to protein loading [14].
Even though the physiological relevance of the phosphotransferase
activity is questionable, the enzyme has been demonstrated to be re-
sponsible for the activation, by phosphorylation, of some nucleoside
analogs inuse as antineoplastic drugs, suchas tiazofurin, 8-azaguanosine,
deoxycoformycin and arabinosyl derivatives [15,16] and antiviral drugs,
such 2′,3′-dideoxyinosine, 2′,3′-dideoxyguanosine, carbovir, acyclovir
[6,15] and amdoxovir, a promising anti-HIV-1 drug [17]. On the other
hand, high cN-II mRNA levels have been correlated with resistance to
nucleoside analogs (NA) during treatment for haematological malig-
nancies and some solid tumours [18–21]. The role of cN-II would be the
dephosphorylation of the cytotoxic mononucleotides produced in the
ﬁrst step of analog activation [18,20,22,23]. Recently Jordheim et al. [24]
proved a direct involvement of cN-II in in vitro dephosphorylation of a
clinically cytotoxic NA, i.e. F-ara-AMP (Fludarabine). On the other hand,
since cN-II seems to interfere also with cytotoxicity of NA prodrugs that
are not its substrates, it is not clear whether, besides the direct effect on
drug metabolism, cN-II may also play an indirect effect mediated by its
inﬂuence on intracellular nucleotide pool [25].
Fluctuations of cN-II activity have also been evidenced in some
pathological conditions including the Lesch–Nhyan syndrome, a neuro-
logical syndrome associated with a complete lack of functional hypo-
xanthine phosphoribosyl transferase (HPRT) and characterised by a
substantial increase of the rate of nucleotide denovo synthesis [26].More
recently several other purine dismetabolisms have been described often
associated with various degree of mental retardation and/or neuromo-
torial dysfunctions [27,28]. Even though many speculations have been
made in the past, no direct proof has been displayed on the linkage
betweenpurine dismetabolism and CNSdysfunction.We believe that the
comprehensionof the role playedbypurinemetabolismenzymes both in
glial andneuronal cells is of fundamental importance not only for a better
understanding of the biochemical mechanisms underlying some pathol-
ogies, but also to improve the outcome of treatment of some therapies.
To better understand the cN-II function we decided to knockdown
the enzyme expression in a human astrocytoma cell line using the RNAi
approach [29–31]. RNAi is a powerful tool to induce loss-of-function of a
speciﬁc protein by inhibiting gene expression post-trascriptionally, and
it revolutionized the study of gene function by target gene knockdown.
Our results clearly demonstrate that cN-II is essential for cell survival in
human astrocytoma cultured cells. In fact, as a consequence of cN-II
silencing, cells start apoptosis, surprisingly without alteration of intra-
cellular nucleotide concentration or energy charge.
2. Materials and methods
2.1. Synthesis of the double-strand oligonucleotides expressing the shRNA sequences
Potential target sequences for Homo sapiens and Rattus norvegicus cN-II mRNA
(NM_012229) were screened using a siRNA designed software tool found in the websitehttp://i.cs.hku.hk/∼sirna/software/sirna.php. We selected three shRNA sequences
speciﬁc for human cN-II, targeting the positions 473, 660 and 1171 respectively in the
cN-II mRNA. As control in our knockdown experiments we synthesised a sequence
expressing an unrelated shRNA previously described [32]. This sequence, BLAST ana-
lysed, showed no match with any human or murine mRNAs.
Each double-strand oligonucleotide was obtained by incubating a mixture of two
complementary oligomers at 93 °C for 15 min and then decreasing the temperature
slowly (about 1-2 °C/min) to reach 25 °C.
The oligomer sequences are as follows:
cN-II_1 (position 660):
top 5′-TTTGAATCTTGAGAAGTATGTAGTTCAAGAGACTACATACTTCTCAAGATTC-
TTTTTT-3′, bottom 5′-CGAAAAAAGAATCTTGAGAAGTATGTAGTCTCTTGAACTACATACTTC-
TCAAGATT-3′;
cN-II_2 (position 1171):
top 5′-TTTGAACTTCAGAGCTTGGATATTCAAGAGATATCCAAGCTCTGAAGTTCTTTTTT-3′,
bottom 5′-CGAAAAAAGAACTTCAGAGCTTGGATATCTCTTGAATATCCAAGCTCTGAAGTT-3′;
cN-II_3 (position 473):
top 5′-TTTGCCTACCAGAGACCTACCTGTTCAAGAGACAGGTAGGTCTCTGGTAGG-
CTTTTTT-3′, bottom5′-CGAAAAAAGCCTACCAGAGACCTACCTGTCTCTTGAACAGGTAGGTCT-
CTGGTAGG-3′.
The unrelated control sequence is:
top 5′-TTTGCACTACCGTTGTTAAGGTGTTCAAGAGACACCTTAACAACGGTAGTGCT-
TTTTT-3′, bottom 5′-CGAAAAAAGCACTACCGTTGTTAAGGTGTCTCTTGAACACCTTAACAA-
CGGTAGTG-3′;
Each oligomer (Sigma Genosys or Invitrogen Custom Primers) contains a 18 nt
(1171) or 19 nt (473 and 660) long sense strand sequence of the ﬁnal siRNA, followed by
a short spacer (5′-TTCAAGAGA-3′), the antisense strand and 6 thymidines used as
terminator signal from RNA polymerase III. The annealing reaction performed with the
two complementary oligomers, generates an insert with BsaI–BstBI cohesive ends used
to perform a directional cloning into the entry vector.
The same procedurewas utilized for the preparation of shRNA for Rattus norvegicus
cN-II targeting the position 667 in mRNA sequence. In this case the sense and antisense
sequences were 22 bp long.
The oligomer sequences for the rat shRNA are as follows:
Rattus cN-II:
top 5′-TTTGAGAAGTATGTAGTCAAAGATGGTTCAAGAGACCATCTTTGACTACA-
TACTTCTCTTTTTT-3′, bottom 5′-CGAAAAAAGAGAAGTATGTAGTCAAAGATGGTCTCTT-
GAACCATCTTTGACTACATACTTCT-3′.
2.2. Generation of recombinant adenoviral plasmid
The pENTR/D-Topo vector (Invitrogen) was previously modiﬁed by adding an
expression cassette containing the U6 promoter, the lacZ sequence between the
restriction sites for BsaI and BstBI and the Cytomegalovirus promoter followed by the
enhanced green ﬂuorescent protein (EGFP) coding sequence to obtain the pENTR/U6-
lacZ-CMV-EGFP vector (kindly provided by Dr. Lin Liu from Oklahoma State Univ., OK,
USA). This vector was digested ﬁrst with BsaI (New England Biolabs) and second with
BstBI (New England Biolabs). The digested vector, SAP treated (Shrimp Alcaline
Phosphatase, Promega) and puriﬁed from agarose gel, was used to clone the insert
expressing the shRNA sequence, to obtain the pENTR/U6-sh-CMV-EGFP vectors. The
ligation reaction was performed by incubating both digested plasmid and insert, at the
ﬁnal concentration of 2 mM and 1 mM respectively, at 16 °C for 18 h in the presence of
T4 DNA Ligase (Promega) in the appropriate buffer. 1 μl of this reaction, containing
about 30 ng of DNA, was used to transform, by heat shock method, 200 μl chemically
competent E. coli DH5α strain in accord to Sambrook et al. [33]. The cells were
immediately placed in 800 μl of LB-broth and grown at 37 °C for 1 h. The cell suspension
was then plated in 10 cm Petri dishes containing LB-agar in the presence of 30 μg/ml
kanamycin. After 18 h growth at 37 °C, 3–4 colonies from each plate were collected and
grown in LB-broth kanamycin added for 16 h. The puriﬁed plasmid was used directly for
the recombinational cloning with the pAd/PL-DEST (Invitrogen) to obtain the pAd/U6-
sh-CMV-EGFP vector. 1 μl of the reaction product was used to transform competent
E. coli DH5α. The transformed cells were plated in LB agar containing 50 μg/ml
Ampicillin. All described clones have been veriﬁed by DNA sequencing.
2.3. Cell culture and Adenovirus production in mammalian cells
293A, a human kidney epithelial cell line used as packaging cell line for virus
production, was purchased from Invitrogen. The human astrocytoma cell line (ADF) was
kindly provided by Dr.W.Malorni, Istituto Superiore di Sanità (Roma, Italy). The rat lung
epithelial cell line, L2, was purchased from ECACC (European Collection and Cell
Culture).
293A cells were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM)
supplementedwith 10% Foetal Bovine Serum (FBS; Gibco-Invitrogen) 2mM L-glutamine
(Gibco-Invitrogen), 0.1 mMMEMNon-Essential Amino Acids (Gibco-Invitrogen), 100 U/
ml Penicillin and 100 μg/ml Streptomycin (Gibco-Invitrogen). ADF cells weremaintained
in RPMImedium (Gibco-Invitrogen) supplementedwith 10% FBS and 200U/ml Penicillin
and 200 μg/ml Streptomycin. L2 cells were mantained in Kaign's modiﬁed Ham's F-12
1531M.G. Careddu et al. / Biochimica et Biophysica Acta 1783 (2008) 1529–1535supplemented with 10% FBS, 2 mM Glutamine, 100 U/ml Penicillin and 100 μg/ml
Streptomycin. Cells were grown at 37 °C in a humidiﬁed 5% CO2/95% air atmosphere.
Three days before transfection the 293A cells, at 70–80% conﬂuence, were
trypsinised, diluted in fresh medium and plated in a 6-well plate (2 ml/well) at con-
centration of 2×105 cells/well. 1 h before transfection fresh medium was provided to
the cells at approximately 70% conﬂuence. The adenoviral vector, containing the cas-
sette of interest, was digested with PacI restriction enzyme (New England Biolabs).
1.6 μg of puriﬁed PacI-linearized pAd/U6-sh-CMV-EGFP were transfected using
calcium phosphate method in accord to Spector et al. [34]. When 80% of cytopathic
effects were reached, adenovirus-containing cells and media were harvested and the
crude viral lysate was prepared by 3 freeze/thaw cycles followed by centrifugation. A
higher titre adenoviral stock was obtained by re-infecting the packaging cells.
Infectious titres of viral lysates, determined by detection of GFP expressing cells 36 h
after infection in 293A cells with serial viral lysate dilutions, ranged from 1.0×109 to
3.0×109 plaque-forming units (pfu)/ml.
2.4. Transduction experiments
ADF cells were used as human cell line of choice to transduce the viruses at
differentMultiplicity of Infection (MOI). MOI of 30 ensured 100% transduction efﬁciency
observing cultured cell ﬂuorescence due to the expression of GFP. At different times
from transduction, the cells were harvested and analysed.
For the experiment in rat cells we selected the L2 cells transduced at MOI of 30
ensuring, also in this cell line, 100% transduction efﬁciency.
2.5. mRNA detection
Total RNA was isolated from cells using RNAgents® Total RNA Isolation System
(Promega) following the manufacturer's instructions and quantiﬁed by UV absorbance
spectroscopy. After being treated with DNase (Promega), 1 μg of total RNA was retro-
transcribed into cDNA using ImProm II reverse transcriptase (Promega) in the presence of
100 ng18-meroligo(dT). 2 μl of this cDNAwere assayed for cN-II expression in thepresence
of 0.2mMeach dNTP,1× PCR buffer containing 1.5mMMgCl2, 0.2mM speciﬁc primers and
1 U GoTaq DNA Polymerase (all reagents are from Promega). For normalization of RNA
loading, the housekeeping gene GAPDH was also ampliﬁed for each cDNA samples. The
primer sequences are the following: human cN-II forward: 5′-TGGAGTGATCGGTTACA-
GAAT-3′ (13–33); reverse: 5′-AGCAACTCCTGGGGATAGC-3′ (260–279); Rattus norvegicus
cN-II forward 5′-TGGAGTACCGCTTACAGAACG-3′(13–33); reverse 5′-TTGAGCAGCTCCT-
GAGGATAGC-3′ (263–284); GAPDH, forward 5′-GAAGGTGAAGGTCGGAGTC-3′ (81–99),
reverse5′-GAAGATGGTGATGGGATTTC-3′ (287–306). ThePCRampliﬁcationwasperformed
using the following conditions: initial denaturation step at 95 °C for 5 min, 30 cycles of
denaturation at 95 °C for 30 s, annealing at 58 °C for 30 s and extension at 72 °C for 30 s,
followed by aﬁnal elongation step of 72 °C for 5min. After ampliﬁcation 5 μl aliquot of each
sample was electrophoresed on 1.2% agarose gels and PCR fragments were visualised by
ethidium bromide staining. The predicted band size are 250 bps for human and Rattus
norvegicus cN-II and 226 bps for human and Rattus norvegicus GAPDH.
2.6. Cell crude extract preparation and enzyme activity assay
ADF cells were kept in 60-mm dishes and at different times fromvirus transduction
were scraped off in the presence of 250 μl 100 mM Tris HCl pH 7.4 and transferred in aFig. 1. cN-II mRNA levels in ADF cells compared with those detected in cells transduced with t
were transduced with Ad-sh473, Ad-sh660, Ad-sh1171 and control Ad-shc viruses. The lowe
different MOI values are indicated (just two extreme values for the control virus). GAPD
quantiﬁcation of the gel. The bars represent the mean±SEM of three different experiments. S
viruses. Abbreviation used: 473 is Ad-sh473, 660 is Ad-sh660, 1171 is Ad-sh1171 and shc is1.5 ml tube. Crude extracts were obtained by 3 freeze/thaw cycles followed by
centrifugation at 10,000 ×g at 4 °C for 40min to pellet the cell debris. Supernatants were
analysed for cN-II activity.
The cN-II phosphotransferase activity was measured as the rate of [8-14C]IMP
formation from 1.4 mM [8-14C] inosine (8000 dpm/nmole), in the presence of 2 mM
IMP, 20 mM MgCl2, 4.5 mM ATP and 5 mM dithiothreitol, as previously described [9].
One unit of enzyme activity is the amount of enzyme which can convert 1 μmol of
substrate per min, under the adopted experimental conditions.
2.7. Measurement of intracellular nucleotides
The metabolites IMP, GMP, AMP, ADP, ATP and Ino were detected in the cellular
extracts by HPLC according to Micheli et al. [35].
ADF cells were seeded in a 6-multi well plate at 2×105 cells/well. When the 80–90%
conﬂuence was reached, the cells were transduced with the adenoviruses at MOI of 30.
72 h after transduction the medium was removed and the cells were scraped off.
2.8. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
The method is based on the ability of metabolically active cells to reduce the MTT
tetrazolium salt, water-soluble, into a purple-coloured, water-insoluble MTT formazan
salt by the mitochondrial enzyme succinate dehydrogenase. Brieﬂy, cells were seeded
in 96-multi well plate at 2.5×104 cells/well in completemedium in order to have 6wells
per experimental condition. At different times from virus transduction, MTT was added
at the culture medium of each well at 0.5 mg/ml ﬁnal concentration and cells were
incubated at 37 °C/5%CO2 for 3 h; the reaction was stopped by replacing the MTT-
containing medium with 100 μl DMSO (Sigma) and the formazan salts were dissolved
by gentle shaking for about 5 min at room temperature. Formazan salts were quantiﬁed
spectrophotometrically by reading the absorbance at 570 nm using the Ultramark
Microplate Systems (Bio-Rad, Hercules, CA, USA). Each experiment was repeated at
least three times.
2.9. Immunoblot analysis
SDS-PAGE was performed following the method of Laemmli [21]. Sample volumes
corresponding to 10 μg of proteins from each sample were applied to a 10% SDS-
polyacrylamide gel. After electrophoresis, Western blotting was performed using PVDF
membrane and processed for immunodetection. Membrane was incubated with
primary cN-II chicken antibody preparation (1:1000) overnight at 4 ° C. Detection of
immunoreactive band was performed by using rabbit anti chicken IgG horseradish
peroxidase-conjugated (1:4000) for 2 h at room temperature. Visualisation was carried
out using ECL kit reactives.
2.10. Apoptosis detection
The apoptosis has been measured as caspase-3 activation and staining the nuclei
with the Hoechst stain solution.
For the caspase-3 assay, at different times after virus transduction, ADF cells were
scraped off and resuspended in the lysis buffer containing 20 mM Tris–HCl pH 7.4,
150 mM NaCl, 1 mM DTT, 5 mM EDTA, 5 mM EGTA, 0.1 mM PMSF, 5 μg/ml Leupeptin,
5 μg/ml Pepstatin A, 1% Triton-X 100 (Sigma). Caspase-3 activation was analysed by ahree potentially silencing viruses and the control virus at different MOI values. ADF cells
r panel shows ethidium bromide-stained gels of the reaction products. In brackets four
H has been used as housekeeping gene. The upper panel shows the densitometric
tatistical signiﬁcance: ⁎⁎⁎pb0.0005, ⁎⁎pb0.005 and ⁎pb0.05 versus ADF grownwithout
Ad-shc.
Fig. 3. A) Cell viability (measured as MTT reduction) and B) cN-II phosphotransferase
activity (PHT) at different times after virus transduction (MOI 30) of ADF cells. All data
are average ± SEM (n=3). Statistical signiﬁcance: ⁎⁎⁎pb0.0005, ⁎⁎pb0.005 versus ADF
grown without viruses. The inset shows the immunoblot analysis of cN-II after 72 h of
virus transduction. Abbreviation used: 660 is Ad-sh660 and shc is Ad-shc.
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at 400 nm.
Apoptotic nuclear morphology was observed by staining with Hoechst 33258. In
order to visualise condensed and fragmented nuclei, cells, 72 h after virus transduction,
were ﬁxed with 4% paraformaldehyde in 10 mM phosphate buffer pH 7.4 (PB), rinsed
with PB, exposed to 1 μg/ml Hoechst 33258 in PB for 30 min at room temperature, and
ﬁnally rinsed with PB and examined under UV illumination with a Zeiss ﬂuorescence
microscope (Axiovert 35).
2.11. Other methods
Densitometric analyses were performed using LabImage 1D 2006 (Kapelan Bio-
Imaging, Halle/Saale, Germany). Statistical analyses were performed using Student's
t test with GraphPad InStat version 4.0 (GraphPad Software, San Diego, CA, USA).
3. Results
3.1. Adenovirus validation in ADF cells
As shown in Fig. 1, we assessed the cN-II knockdown analysing the
mRNA levels at different MOI values, ranging from 8 to 30, in the
astrocytoma ADF cultured cells. Only the Ad-sh660 effectively reduced
the expression of cN-II mRNA, so we decided to use this vector for our
loss-of-function studies in ADF cells.
3.2. cN-II is essential for survival of cultured cells
Since the beginning of our investigation it became evident that cN-
II mRNA reduction in cells was somehow related to some degree of cell
mortality. We therefore investigated on this aspect measuring enzyme
activity, cell viability and mRNA in ADF cells at different times from
virus transduction. Our results show that 53 h after transduction the
amount of cN-II mRNA was reduced to 17.9±0.03% of control in
silenced cells (Fig. 2) while both enzyme activity and cell viability
were still of the same order than controls (Fig. 3). 19 more hours were
necessary to obtain a sensible decrease of cN-II activity from 0.7±
0.026 mU/mg to 0.45±0.046 mU/mg (36% reduction), and of cell
viability up to 0.59±0.01 (fold vs control) in cells transduced with Ad-
sh660, while both controls remained unaffected (Fig. 3). The decrease
in enzyme activity in cells infected with silencing virus is accom-
panied by a substantial decrease of cN-II as demonstrated by
immunoblotting analysis (Fig. 3B — inset).
In order to ascertain if transient knock out of cN-II can be obtained
also in cells of different origin, a rat lung epithelial cell line (L2) wasFig. 2. cN-II mRNA levels measured 24 h and 53 h after transduction of ADF cells with
Ad-sh660 and Ad-shc. The lower panel shows ethidium bromide-stained gels of the
reaction products. The upper panel shows the densitometric quantiﬁcation of the gel.
The bars represent the mean±SEM of three different experiments. Statistical
signiﬁcance: ⁎⁎⁎pb0.0005 versus ADF not transduced grown for 53 h. Abbreviation
used: 660 is Ad-sh660 and shc is Ad-shc.infected with Ad-sh667 and control virus as described in Materials
and methods. The silencing sequence utilised in this experiment was
very similar to that utilised for the human cell line; in fact the two
sequences have 12 bases in common. As shown in Fig. 4 also in the rat
cell line we obtained a relevant decrease of mRNA with the twoFig. 4. cN-II mRNA levels in L2 cells compared with those detected after 53 h in cells
transduced with Ad-sh667 (at two different MOI) and the control Ad-shc virus at
maximum MOI value. The lower panel shows ethidium bromide-stained gels of the
reaction products. In brackets MOI values are indicated. GAPDH has been used as
housekeeping gene. The upper panel shows the densitometric quantiﬁcation of the gel.
The bars represent the mean±SEM of three different experiments. Statistical
signiﬁcance: ⁎⁎⁎pb0.0005 versus L2 grown without viruses. Abbreviation used: 667
is Ad-sh667 and shc is Ad-shc.
Table 1
Levels of purines metabolites and adenylate energy charge values in cell extracts 72 h
after virus transduction
IMPa Inoa AMPa ADPa ATPa E.C.
ADF 4.5±0.34 6.6±2.99 0.95±0.06 22.1±1.5 36.7±5.4 0.79±0.01
shc 4.8±0.71 7.7±2.78 0.81±0.18 24.5±4.8 38.9±4.6 0.80±0.01
660 4.8±0.25 8.1±0.44 0.85±0.11 25.4±0.2 45.3±2.0 0.81±0.006
The analysis was conducted according to [35]. All values are the mean of triplicate
experiments. Abbreviation used: E.C. is adenylate energy charge, 660 is Ad-sh660 and
shc is Ad-shc.
aThe value represents the peak area (arbitrary units) ±SEM measured in the
chromatograms.
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30 and of 25) after 53 h from transduction. Within 20 more hours a
relevant number of cells showed apoptotic morphology (data not
shown).
3.3. Purine metabolite detection
Since the proposed role for cN-II is the regulation of intracellular
concentration of purinenucleotides,wemeasured purine compounds in
ADF cells 72 h after virus transduction. Intracellular purine nucleosides
and nucleotides were measured by HPLC and, surprisingly, we did not
observe any remarkable alteration in the silenced cells compared to the
controls (Table 1). Also the energy charge was unaffected.
3.4. cN-II knockdown induces apoptosis in ADF cultured cells
The occurrence of apoptosis in the cells treated with the silencing
virus was detected by the observation of the nuclear morphology,
after staining with Hoechst 33258. As shown in Fig. 5A, many cells
after 72 h from transductionwith the silencing virus are characterised
by an alteration of the nuclear morphology typical of the apoptotic
cells. ADF cells at the same time after transduction presented aFig. 5. Apoptosis detection in ADF astrocytoma cells. A) Cells 72 h after transduction we
magniﬁcation (20×). Arrow indicates an example of apoptotic cell. Panel B shows cN-II phos
virus transduction (MOI of 30) of cells. All data are average±SEM of three independent exper
Ad-sh660 and shc is Ad-shc.remarkable caspase-3 activation: 639±37 compared to 136±5.7 mU/
mg in control cells (Fig. 5B). A time course of caspase-3 and cN-II
activity clearly shows that the ﬁrst measurable event after decrease of
cN-II mRNA is the decrease of enzyme activity followed by caspase
activation, thus indicating the cN-II silencing as the cause of apoptosis
activation. We chose to measure the activity of the effector caspase-3
since it is known that ADF cells lack the “intrinsic apoptotic pathway”
because of a point mutation in the prodomain region of caspase-9
[36].
4. Discussion
Despite the large amount of data so far collected by a number of
research groups on the role of cytosolic 5′-nucleotidases, many
questions are still waiting for unambiguous answers. 5′-Nucleotidases
have been described as part of a substrate cycle in which deoxyr-
ibonucleotides are continuously degraded by a nucleotidase with
appropriate substrate speciﬁcity and the resulting deoxyribonucleo-
side may either be rephosphorylated by a kinase and ATP or leave the
cell depending on the concentration gradient across the membrane
[3]. Therefore, this substrate cycle regulates the balance between
anabolism and catabolism of deoxyribonucleosides and avoids the
accumulation of dNTP pools. Thus an impairment of a cytosolic nu-
cleotidase activity may well cause a gross alteration of dNTP pools
either in dividing or not dividing cells, potentially leading to serious
consequences. In this line is the observation that a lack of the cytosolic
5′-nucleotidase activity speciﬁc for pyrimidine nucleotides (cN-III),
usually highly expressed in red cells, causes an accumulation of
pyrimidine nucleotides leading to haemolytic anaemia [37]. Further-
more, the in situ modiﬁcation of mdN activity demonstrated that this
nucleotidase regulates the incorporation of thymidine into mitochon-
drial dTTP pool [38]. Among nucleotidases, nevertheless, cN-II
presents several peculiar features. The enzyme not only is widely
expressed among vertebrates but its sequence is peculiarly conserved:
95% of identity of deduced amino acid sequence has been reportedre ﬁxed and stained with Hoechst 33252. The three pictures are taken at the same
photransferase activity (upper) and caspase-3 activation (lower) at different times after
iments. Statistical signiﬁcance: ⁎⁎⁎pb0.0005 versus controls. Abbreviation used: 660 is
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pounds such as ATP, ADP, bisphosphoglycerate, polyphosphates,
phosphate, and bivalent ions such as Cu2+, Zn2+, Ca2+. Hypotheses
have been made on the meaning of this complex regulation but none
of them has found a sound experimental support [9]. cN-II is a
tetrameric enzyme and, interestingly, it has been proposed that en-
zyme activators promote subunit aggregation, while inhibitors such as
phosphate induce disassociation [3]. Overexpression of cN-II in
human embryonal kidney cells was performed in order to deﬁne the
physiological role of this peculiar enzyme, demonstrating that a
10 fold overexpression caused a decrease of about 20% of both purine
and pyrimidine ribo- and deoxyribo-nucleotides, while an over-
expression of more than 10 fold was impossible to obtain probably
because an adverse effect on cell viability [39]. This observation,
although not conclusive, appeared to be in linewith a direct or indirect
involvement of cN-II in the regulation of nucleotide pools. Analysing
the large amount of data on cN-II distribution, we observed that cells
or organs completely lacking cN-II activity have never been described
and that an increase of several folds above controls of cN-II activity has
been associated to severe pathologies such as cancer and neurological
disorders [13,26]. All these observations point to an essential, very
critical role played by this cytosolic nucleotidase.
In order to investigate on the physiological role of the enzyme, we
decided to knockdown cN-II using the RNAi technique and to analyse
the cellular modiﬁcations followed by the reduction of this speciﬁc
enzyme. As cell model we utilised ADF cells since the severe
neurological defects always associated to purine dismetabolisms
point to a fundamental, so far uncompletely unraveled role played
by purine compounds in CNS cells. We obtained a constitutive siRNA
intracellular synthesis mediated by adenoviral vectors. Three inde-
pendent viruses expressing shRNAs against cN-II were generated in
order to select the best silencing sequence. Only one of them, targeting
the cN-II mRNA starting at the position 660, was effective in lowering
cN-II messenger in ADF cell lines. We obtained an evident mRNA
reduction 53 h after virus transduction and 17 h later we also noticed a
signiﬁcant reduction of enzyme activity indicating that cN-II is a long
life protein. Since the beginning of our experiments it was evident that
cN-II reduction in the ADF cells caused a decrease of cell viability. This
result has also been evidenced knocking down cN-II in Rattus
norvegicus cells (L2 cell line), thus indicating that the fundamental
role played by cN-II is not peculiar of glial cells. As far as we know cN-II
is the only member of the 5′-nucleotidase large family proved to be
essential for survival.
We also demonstrated that the consequence of the decrease of cN-
II expression was the activation of the apoptotic pathway showing
both modiﬁcations of cell morphology and activation of caspase-3
activity. Wemeasured the nucleoside and nucleotide levels in silenced
cells ﬁnding no signiﬁcant difference with respect to the controls. We
also exposed ADF cells to Ad-sh660 for more that 72 h but the massive
cell death made impossible a correct evaluation of intracellular purine
metabolites. It is therefore evident that the cell death is not a
consequence of a gross alteration of intracellular purine content.
Furthermore, it has been previously demonstrated that in ADF cells a
decrease of more than 30% of adenylate content does not affect cell
viability [40]. On the other hand, it must be pointed out that the
substrate cycle in which cN-II is involved does not include a
nucleoside kinase but includes two enzymes: purine nucleoside
phosphorylase, responsible for the phosphorolytic cleavage of inosine
or guanosine generated by cN-II activity, and HPRT responsible for the
phosphoribosylation of purine bases. This cycle is involved not only in
the regulation of IMP and GMP but also of PRPP and ribose-1-
phosphate intracellular concentrations [41]. PRPP is determinant for
the rate of both salvage and de novo synthesis, while ribose-1-
phosphate may be involved both in the ribosylation of bases through
nucleoside phosphorylases or in energy repletion [42]. Presently, we
may hypothesise that the cN-II knockdown caused a ﬂuctuation of ahitherto unidentiﬁed critical purine metabolite or that cN-II, besides
its well known catalytic activity, may play a different, so far
unreported role, regulating vital functions. Work is in progress to
identify the critical metabolite or the yet unknown role played by cN-
II. This should ﬁnally explain the reasons for the high conservation of
the enzyme sequence, the widespread distribution, the lack of mutant
cells devoid of cN-II activity, the complex regulation and the death of
cells following relevant enzyme overexpression or knockdown.
ADF cells show resistance to a number of chemotherapeutic agents
commonly leading to apoptosis in different cancer cells. This
resistance has been attributed to a defect in the intrinsic apoptosis
pathway caused by point mutation in the prodomain region of
caspase-9 [36]. The activation of apoptosis caused by the knockdown
of cN-II opens a new possibility for developing strategies aimed at
overcoming tumour invasiveness and resistance to chemotherapy.
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